Comparative Pharmacology
Head-to-head clinical analysis: IFEX versus MELPHALAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFEX versus MELPHALAN HYDROCHLORIDE.
IFEX vs MELPHALAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IFEX (ifosfamide) is an alkylating agent that crosslinks DNA strands, inhibiting DNA synthesis and transcription. It requires hepatic activation via CYP3A4 to form active metabolites (ifosfamide mustard and acrolein).
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
1.2 g/m2 intravenously daily for 5 consecutive days every 3 weeks, or 5 g/m2 as a 24-hour continuous infusion every 3 weeks.
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours in adults with normal renal function; prolonged in renal impairment.
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
Renal: approximately 50-70% of the administered dose is excreted in urine as unchanged drug; biliary/fecal excretion is minimal, accounting for less than 5%.
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Category C
Category D/X
Alkylating Agent
Alkylating Agent